EW - These Analysts Boost Their Forecasts On Edwards Lifesciences Following Q4 Results | Benzinga
Edwards Lifesciences Corporation (NYSE: EW) reported in-line earnings for its fourth quarter on Tuesday.
Edwards Lifesciences posted adjusted earnings of 64 cents per share, in-line with market expectations of 64 cents per share. The company’s quarterly sales came in at $1.53 billion versus estimates of $1.50 billion, according to data from Benzinga Pro.
"In 2023, our team made significant progress advancing transformational therapies for patients while delivering strong financial performance. Full year sales increased 12 percent, including impressive growth across each of our four product groups," said Bernard Zovighian, Edwards’ CEO. "We exited the year with strong ...